title: Ziyuglycoside II-induced apoptosis in human gastric carcinoma BGC-823 cells by regulating Bax/Bcl-2 expression and activating caspase-3 pathway.
abstract: Ziyuglycoside II is an active compound of Sanguisorba officinalis L. that has anti-inflammation, antioxidation, antibiosis, and homeostasis properties. We report here on the anticancer effect of ziyuglycoside II on human gastric carcinoma BGC-823 cells. We investigated the effects of ziyuglycoside II on cell growth, cell cycle, and cell apoptosis of this cell line. Our results revealed that ziyuglycoside II could inhibit the proliferation of BGC-823 cells by inducing apoptosis but not cell cycle arrest, which was associated with regulation of Bax/Bcl-2 expression, and activation of the caspase-3 pathway. Our study is the first to report the antitumor potential of ziyuglycoside II in BGC-823 gastric cancer cells. Ziyuglycoside II may become a potential therapeutic agent against gastric cancer in the future.
authors: Affiliated Hangzhou Hospital, Department of General Surgery, Nanjing Medical University, Hangzhou, China.
authors: A K
authors: AK
authors: Zhu
authors: H
authors: H
authors: Zhou
authors: J Z
authors: JZ
authors: Xia
authors: H C
authors: HC
authors: Jin
authors: K
authors: K
authors: Wang
authors: J
authors: J
authors: Yan
authors: J B
authors: JB
authors: Zuo
authors: X
authors: X
authors: Zhu
authors: T
authors: T
authors: Shan
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D002277:Carcinoma / Q000188:drug therapy; D053148:Caspase 3 / Q000187:drug effects / Q000378:metabolism*; D061945:Caspase Inhibitors / Q000378:metabolism; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D005470:Fluorometry; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000187:drug effects / Q000378:metabolism*; D031993:Sanguisorba / Q000737:chemistry; D012503:Saponins / Q000494:pharmacology*; D015398:Signal Transduction / Q000187:drug effects*; D013274:Stomach Neoplasms / Q000188:drug therapy; D051028:bcl-2-Associated X Protein / Q000187:drug effects / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D061945:Caspase Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2; D012503:Saponins; D051028:bcl-2-Associated X Protein; C000588918:ziyuglycoside II; D053148:Caspase 3; D005472:Fluorouracil
references: Curr Treat Options Oncol. 2012 Sep;13(3):377-89
references: 22552927
references: Gastroenterol Clin North Am. 2009 Mar;38(1):153-67, x
references: 19327573
references: DNA Cell Biol. 2013 Feb;32(2):50-7
references: 23347444
references: Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S105-14
references: 14508087
references: Cell Death Differ. 2000 Sep;7(9):761-72
references: 11042671
references: Neurosci Bull. 2012 Feb;28(1):14-24
references: 22233886
references: Lung Cancer. 2010 May;68(2):137-45
references: 20015572
references: Int J Mol Med. 2010 Aug;26(2):201-8
references: 20596599
references: Biosci Biotechnol Biochem. 2008 Feb;72(2):303-11
references: 18256460
references: J Surg Oncol. 2011 Nov 1;104(6):692-8
references: 21713780
references: Molecules. 2012 Nov 23;17(12):13917-22
references: 23178307
references: J Gastroenterol Hepatol. 2007 Jul;22(7):970-2
references: 17524038
references: Complement Ther Med. 2009 Apr;17(2):92-120
references: 19185267
references: Expert Opin Ther Targets. 2012 Mar;16 Suppl 1:S79-89
references: 22316502
references: Mol Med Rep. 2012 Sep;6(3):670-4
references: 22710351
references: Eur J Med Chem. 2011 Oct;46(10):4769-807
references: 21889825
references: Int J Biol Macromol. 2012 Nov;51(4):484-8
references: 22659266
references: Curr Pharm Biotechnol. 2012 Jun;13(8):1426-38
references: 22423614
references: Biochim Biophys Acta. 2004 Mar 1;1644(2-3):229-49
references: 14996506
references: Cell Death Differ. 2009 Aug;16(8):1075-82
references: 19521421
references: Cancer Treat Rev. 2010 Aug;36(5):384-92
references: 20176443
references: Oncogene. 1994 Jun;9(6):1791-8
references: 8183578
references: Future Oncol. 2010 Apr;6(4):527-37
references: 20373867
references: Expert Rev Anticancer Ther. 2007 Oct;7(10):1369-78
references: 17944563